AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1100041 — intervention group
Group type: EXPERIMENTAL
Intervention: Plimasin
Number of subjects: 26
Study 1100041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrobenzamine
Number of subjects: 26
Study 1100041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery
Number of subjects: 10873
Study 31588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy after breast conservation
Number of subjects: 10873
Study 31588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 10873
Study 31588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 10873
Study 31588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncotype DX
Number of subjects: 10873
Study 31588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy
Number of subjects: 10873
Study 31588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral prophylactic mastectomy
Number of subjects: 10873
Study 31588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordering of Oncotype DX
Number of subjects: 10873
Study 31588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of endocrine therapy
Number of subjects: 10873
Study 31588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, black race, higher Charlson Comorbidity Index, high tumor grade and stage of disease, undergoing total mastectomy
Number of subjects: 10873
Study 31588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Residing in a higher income area; having progesterone receptor-positive tumors; receipt of chemotherapy, radiotherapy, and endocrine therapy
Number of subjects: 10873
Study 30945623 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg olanzapine (arm A; n=27)
Number of subjects: 81
Study 30945623 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg olanzapine plus 4 mg dexamethasone (arm B; n=27)
Number of subjects: 81
Study 30945623 — intervention group
Group type: COMPARATOR
Intervention: 8 mg dexamethasone (reference arm C; n=27)
Number of subjects: 81
Study 30945623 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Living Index‐Emesis (FLIE) questionnaire
Number of subjects: 81
Study 30945623 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's satisfaction with antiemetic coverage
Number of subjects: 81
Study 28260692 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized glycemic goals
Number of subjects: 278
Study 25185788 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic humeral centering (DHC)
Number of subjects: 0
Study 25185788 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific mobilization
Number of subjects: 0
Study 23286749 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe head injury ≤ 1 year before diagnosis
Number of subjects: 4004
Study 23286749 — intervention group
Group type: COMPARATOR
Intervention: Severe head injury > 3 years before diagnosis
Number of subjects: 4004
Study 23286749 — intervention group
Group type: COMPARATOR
Intervention: Subtypes of head injury or repeated injuries > 3 years before diagnosis
Number of subjects: 4004
Study 21631509 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (oral hygiene instructions and subgingival scaling and root planing)
Number of subjects: 36
Study 21631509 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study 18832879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 1111
Study 18832879 — intervention group
Group type: COMPARATOR
Intervention: Thymidine analogue-containing regimen (control)
Number of subjects: 1111
Study 16476678 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (n = 24) for 15 days before FSH treatment
Number of subjects: 49
Study 16476678 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (n = 25) for 15 days before FSH treatment
Number of subjects: 49
Study 13129422 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG and GER (Group II)
Number of subjects: 110
Study 13129422 — intervention group
Group type: COMPARATOR
Intervention: CABG alone (Group I)
Number of subjects: 110
Study 10947032 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-titrating, self-adjusting device (APAP)
Number of subjects: 60
Study 10947032 — intervention group
Group type: COMPARATOR
Intervention: Standard nasal continuous positive airway pressure (CPAP)
Number of subjects: 60
Study 9032214 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal asthma patients
Number of subjects: 0
Study 9032214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal asthma patients
Number of subjects: 0
Study 9032214 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 8321836 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine extended-release (ER) tablets 10 mg under fasting conditions
Number of subjects: 8
Study 8321836 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine extended-release (ER) tablets 10 mg under nonfasting conditions
Number of subjects: 8
Study 8321836 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine extended-release (ER) tablets 10 mg
Number of subjects: 8
Study 8321836 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine extended-release (ER) tablets 10 mg with food
Number of subjects: 8
Study 3963319 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flunitrazepam
Number of subjects: 600
Study 3963319 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentobarbital
Number of subjects: 600
Study 3963319 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral physiological NaCl solution
Number of subjects: 600
Study 3963319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pethidine
Number of subjects: 600
Study 3963319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular droperidol/fentanyl
Number of subjects: 600
Study 3963319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular physiological NaCl solution
Number of subjects: 600
Study 3963319 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral premedication
Number of subjects: 600
Study 3963319 — intervention group
Group type: COMPARATOR
Intervention: Parenteral premedication
Number of subjects: 600
Study 29730741 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (BT) with highly mineralized sulfate water
Number of subjects: 100
Study 29730741 — intervention group
Group type: COMPARATOR
Intervention: Tap water (control group)
Number of subjects: 100
Study 29730741 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (BT)
Number of subjects: 100
Study 27279970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sombeza Water and Sanitation Improvement Program (SWASIP)
Number of subjects: 250
Study 24401359 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup A (etched and primed, composite resin applied)
Number of subjects: 160
Study 24401359 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup C (etched, primed, contaminated, composite resin applied)
Number of subjects: 160
Study 24401359 — intervention group
Group type: COMPARATOR
Intervention: Subgroup B (etched, contaminated with artificial saliva, primed, composite resin applied)
Number of subjects: 160
Study 24401359 — intervention group
Group type: COMPARATOR
Intervention: Subgroup D (etched, primed, contaminated, primer applied a second time, composite resin applied)
Number of subjects: 160
Study 22519922 — intervention group
Group type: EXPERIMENTAL
Intervention: Bavisant 1 mg/day
Number of subjects: 430
Study 22519922 — intervention group
Group type: EXPERIMENTAL
Intervention: Bavisant 3 mg/day
Number of subjects: 430
Study 22519922 — intervention group
Group type: EXPERIMENTAL
Intervention: Bavisant 10 mg/day
Number of subjects: 430
Study 22519922 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg/day
Number of subjects: 430
Study 22519922 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS Methylphenidate 54 mg/day
Number of subjects: 430
Study 22519922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 20511610 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous methotrexate (scMTX)
Number of subjects: 151
Study 20511610 — intervention group
Group type: COMPARATOR
Intervention: ciclosporin added to oral methotrexate (MTX)
Number of subjects: 151
Study 19004157 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Survey
Number of subjects: 375
Study 19004157 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Survey plus Contract
Number of subjects: 375
Study 19004157 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Survey plus Consult
Number of subjects: 375
Study 16171716 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiwire gamma camera (MWGC) with motion correction
Number of subjects: 100
Study 16171716 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiwire gamma camera (MWGC) without motion correction
Number of subjects: 100
Study 16171716 — intervention group
Group type: COMPARATOR
Intervention: Resting left ventricular (LV) ejection fraction (EF)
Number of subjects: 100
Study 16171716 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak exercise EF by MWGC uncorrected
Number of subjects: 100
Study 16171716 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak exercise EF by MWGC corrected
Number of subjects: 100
Study 12889354 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (20 mg/daily)
Number of subjects: 189
Study 12889354 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of leflunomide and methotrexate
Number of subjects: 189
Study 12889354 — intervention group
Group type: EXPERIMENTAL
Intervention: Detralex in combination with methotrexate
Number of subjects: 189
Study 10471542 — intervention group
Group type: EXPERIMENTAL
Intervention: Texx 300
Number of subjects: 35
Study 10471542 — intervention group
Group type: EXPERIMENTAL
Intervention: Jarsin 300
Number of subjects: 35
Study 10471542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 8707552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg
Number of subjects: 30
Study 8707552 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 50 mg plus promethazine 25 mg
Number of subjects: 30
Study 8707552 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 30
Study 1873003 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 to 8 mg perindopril given once daily
Number of subjects: 20
Study 1873003 — intervention group
Group type: COMPARATOR
Intervention: 25 to 50 mg captopril given twice daily
Number of subjects: 20
Study 6375370 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP/STX (cotrimoxazole)
Number of subjects: 63
Study 29908708 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF in patients ≥75 years
Number of subjects: 622
Study 29908708 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age group
Number of subjects: 622
Study 29908708 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical parameters (age, pulmonary rales, systolic blood pressure, cause of heart failure, osteoporosis, current smoking, NT‐proBNP, haemoglobin, QRS width, heart rhythm)
Number of subjects: 622
Study 29908708 — intervention group
Group type: COMPARATOR
Intervention: Symptom history and clinical examination alone
Number of subjects: 622
Study 26847139 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic testing
Number of subjects: 0
Study 26847139 — intervention group
Group type: COMPARATOR
Intervention: Routine practice without urodynamic testing
Number of subjects: 0
Study 25247335 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day for 12 weeks)
Number of subjects: 281
Study 22614228 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (1,000 mg·d⁻¹ for 8.5 days)
Number of subjects: 16
Study 22614228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20233179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clotrimazole troches 10 mg taken three times daily for 5 days
Number of subjects: 10
Study 20233179 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam 2 mg or intravenous midazolam 0.025 mg kg(‐1) without clotrimazole
Number of subjects: 10
Study 18554207 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltage mapping-guided endomyocardial biopsy (EMB)
Number of subjects: 22
Study 18554207 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltage mapping
Number of subjects: 22
Study 17968997 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 18
Study 17968997 — intervention group
Group type: COMPARATOR
Intervention: Control (no physiotherapy)
Number of subjects: 18
Study 17968997 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy and Control
Number of subjects: 18
Study 14992842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomics training
Number of subjects: 50
Study 14992842 — intervention group
Group type: COMPARATOR
Intervention: Pre- and posttests without training (Control)
Number of subjects: 50
Study 10594437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask using a fibreoptic bronchoscope (group L)
Number of subjects: 40
Study 10594437 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope and gum elastic bougie (group C)
Number of subjects: 40
Study 9355948 — intervention group
Group type: EXPERIMENTAL
Intervention: semirigid mini-endoscope and Swiss Lithoclast
Number of subjects: 147
Study 9355948 — intervention group
Group type: COMPARATOR
Intervention: conventional rigid ureteroscope and ultrasound
Number of subjects: 147
Study 8210718 — intervention group
Group type: EXPERIMENTAL
Intervention: ketotifen 1 mg b.i.d.
Number of subjects: 26
Study 8210718 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study 3534848 — intervention group
Group type: EXPERIMENTAL
Intervention: Capozide (50 mg captopril and 25 mg hydrochlorothiazide)
Number of subjects: 63
Study 3534848 — intervention group
Group type: COMPARATOR
Intervention: Moduretic (50 mg hydrochlorothiazide and 5 mg amiloride)
Number of subjects: 63
Study 31267293 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 1327
Study 31267293 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1327
Study 28039477 — intervention group
Group type: EXPERIMENTAL
Intervention: New risk assessment model for PSA 4-10 ng/mL
Number of subjects: 702
Study 28039477 — intervention group
Group type: EXPERIMENTAL
Intervention: New risk assessment model for PSA 10-50 ng/mL
Number of subjects: 702
Study 28039477 — intervention group
Group type: COMPARATOR
Intervention: PSA alone for PSA 4-10 ng/mL
Number of subjects: 702
Study 28039477 — intervention group
Group type: COMPARATOR
Intervention: PSA alone for PSA 10-50 ng/mL
Number of subjects: 702
Study 25727914 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (COL) 20g per day for 4 weeks
Number of subjects: 20
Study 25727914 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic/isomacronutrient placebo (PLA)
Number of subjects: 20
Study 23786793 — intervention group
Group type: COMPARATOR
Intervention: Alzheimer's disease (AD) patients
Number of subjects: 38
Study 23786793 — intervention group
Group type: COMPARATOR
Intervention: Mild cognitive impairment (MCI) patients
Number of subjects: 38
Study 23786793 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal controls (NC)
Number of subjects: 38
Study 23786793 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of perceptual and response interference effects
Number of subjects: 38
Study 20299114 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3528
Study 20299114 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 3528
Study 20299114 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitor use
Number of subjects: 3528
Study 20299114 — intervention group
Group type: COMPARATOR
Intervention: Nonuse of glycoprotein IIb/IIIa inhibitor
Number of subjects: 3528
Study 18992183 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural frequencies
Number of subjects: 285
Study 18992183 — intervention group
Group type: COMPARATOR
Intervention: Percentages
Number of subjects: 285
Study 18992183 — intervention group
Group type: COMPARATOR
Intervention: Verbal descriptors
Number of subjects: 285
Study 16866127 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based approach in Orthodontics
Number of subjects: 0
Study 16866127 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 0
Study 12938639 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebif 22 micrograms three times a week for 1 year
Number of subjects: 167
Study 10951448 — intervention group
Group type: EXPERIMENTAL
Intervention: STIR MRI
Number of subjects: 90
Study 10951448 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative assessments of signal intensity ratio (SIR) from STIR MRI
Number of subjects: 90
Study 10951448 — intervention group
Group type: COMPARATOR
Intervention: EMG
Number of subjects: 90
Study 9165806 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 82
Study 9165806 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 82
Study 9165806 — intervention group
Group type: COMPARATOR
Intervention: Comparison between TT and PMR
Number of subjects: 82
Study 8464977 — intervention group
Group type: EXPERIMENTAL
Intervention: Back injury prevention program including education, training, physical fitness activities, and ergonomic improvement.
Number of subjects: 205
Study 8464977 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 205
Study 8464977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-benefit analysis of the back injury prevention program.
Number of subjects: 205
Study 2939239 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef (1 g intravenous injection at induction of anaesthesia)
Number of subjects: 431
Study 2939239 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline (peritoneal and wound lavage)
Number of subjects: 431
Study 31733781 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal approach including patient education, manual therapy, therapeutic exercise programs, and orthotic provision
Number of subjects: 0
Study 30106369 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM+)
Number of subjects: 12
Study 30106369 — intervention group
Group type: COMPARATOR
Intervention: No Remote Monitoring (RM-)
Number of subjects: 12
Study 27352489 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Zhongliao (BL 33) and Huiyang (BL 35)
Number of subjects: 42
Study 27352489 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture and placebo EA
Number of subjects: 42
Study 25226004 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA)
Number of subjects: 24
Study 25226004 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 24
Study 22776534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT, 16 sessions)
Number of subjects: 0
Study 22776534 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (30-60 mg/d)
Number of subjects: 0
Study 22776534 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/d)
Number of subjects: 0
Study 22776534 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and antidepressant medication (for non-remitters)
Number of subjects: 0
Study 20116697 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable plate
Number of subjects: 272
Study 20116697 — intervention group
Group type: COMPARATOR
Intervention: Nonresorbable plate
Number of subjects: 272
Study 17621017 — intervention group
Group type: COMPARATOR
Intervention: Radiosurgery (RS)
Number of subjects: 39
Study 17621017 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgery (MS)
Number of subjects: 39
Study 15054512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariporide 20 mg
Number of subjects: 141
Study 15054512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariporide 80 mg
Number of subjects: 141
Study 15054512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariporide 120 mg
Number of subjects: 141
Study 15054512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 11850979 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic hormone stimulation test
Number of subjects: 40
Study 9758074 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration pain provocation
Number of subjects: 78
Study 9758074 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 78
Study 9758074 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined evaluation of vibration pain provocation and MRI
Number of subjects: 78
Study 7949544 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous proliferation (SP) of peripheral blood mononuclear cells (PBMC) in patients with mild episodes of clinical acute rejection (n=2)
Number of subjects: 22
Study 7949544 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous proliferation (SP) of PBMC in liver transplant patients
Number of subjects: 22
Study 7949544 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous proliferation (SP) of PBMC in patients with systemic infections
Number of subjects: 22
Study 7949544 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous proliferation (SP) of PBMC in patients with elevated TAC‐A score (n=8)
Number of subjects: 22
Study 7949544 — intervention group
Group type: EXPERIMENTAL
Intervention: SP of PBMC in patients treated with anti‐interleukin‐2‐receptor antibody, BT563 (n=8)
Number of subjects: 22
Study 7949544 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between SP of PBMC and TAC‐A score
Number of subjects: 22
Study 2884410 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA Plasmodium falciparum sporozoite vaccine (FSV‐1) at doses of 10 to 800 micrograms
Number of subjects: 15
Study 2884410 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA Plasmodium falciparum sporozoite vaccine (FSV‐1) at 800 micrograms
Number of subjects: 15
Study 2884410 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA Plasmodium falciparum sporozoite vaccine (FSV‐1) with a fourth dose
Number of subjects: 15